Mapping of the human genome and the development of next generation sequencing (NGS) have led to advances in screening, pharmacogenetics and targeted therapies. Dr Galibert describes the impact of these advances on precision medicine, and the technological, regulatory, ethical and financial issues they have raised.

Summary

Introduction : Definitions & Objectives of the colloquium: Selective choices among relevant areas with established therapeutic progress. Dominique BELLET et Jean-Paul TILLEMENT

New diagnostic and Therapeutic Technologies

Integration of individual genetic and kinetic characteristics for the pharmacological optimization of drug use. Pierre MARQUET

Toward precision medicine for age-related disease: standardized geriatric assessment. Fati NOURHASHEMI

Genomic and precision medicine: setting problems and perspectives. Francis GALIBERT

Managing drug interactions: a clinical decision support system. Jacques TURGEON

Therapeutic targeting of Interleukin 17: An example of translational medicine. Pierre MIOSSEC

Realities and perspetives of precision medicine

Type 2 diabetes and hypercholesterolemia. André SCHEEN

Should we sequence each patient's tumour?  Christophe LE TOURNEAU

Kidney transplantation: an emblematic example of precision medicine to solve an increasingly complex situation. Thierry HAUET

Gene, cellular and stem-cell therapies: perspectives and limits. Salima HACEIN-BEY

Precision Medicine: which applications, cost and targeted populations? Jean-Pierre MICHEL

Organizers
Pr Dominique Bellet, Pr Jean-Paul Tillement
Authors
Francis Galibert, Rennes
Organizers
Pr Dominique Bellet, Pr Jean-Paul Tillement
Authors
Francis Galibert, Rennes
Category
The patient
Publication type
Proceedings
Year
2017
Download the publication